Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Published Online: 2025-03-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Anwen Xiong•Baiyong Li•Baogang Liu•Bolin Chen•Caicun Zhou•Chengzhi Zhou•Daqiang Sun•Dingzhi Huang•Dongmei Lu•Gaofeng Li•Hongzhong Yang•Hua Zhong•Hui Ge•Jianhua Chen•Jie Li•Jie Yang•Jifang Yao•Jing Wang•Jinliang Wang•Jinlu Shan•Jiqing Hao•Jun Yao•Junqiang Chen•Lei Wang•Ligong Nie•Lin Wu•Michelle Xia•Ming Zhou•Mingxiu Hu•Qian Chu•Qin Shi•Qing Bu•Xiaodong Mei•Xiaohong Ai•Xingya Li•Xinmin Yu•Xuewen Liu•Yanhong Shang•Yanqiu Zhao•Ying Cheng•Yinghua Ji•Yu Lin•Yulan Sun•Zhengxiang Han•Zhongmin Maxwell Wang
